Genetic variability in cisplatin metabolic pathways and outcome of locally advanced head and neck squamous cell carcinoma patients
AMC Ferreira, JMC Altemani, LT Macedo… - Scientific Reports, 2023 - nature.com
Advanced head and neck squamous cell carcinoma (HNSCC) patients have been treated
with cisplatin (CDDP) chemoradiation, and the variability of treatment effects has been …
with cisplatin (CDDP) chemoradiation, and the variability of treatment effects has been …
Association of Clinical Aspects and Genetic Variants with the Severity of Cisplatin-Induced Ototoxicity in Head and Neck Squamous Cell Carcinoma: A Prospective …
LT Macedo, EFD Costa, BF Carvalho, GJ Lourenço… - Cancers, 2023 - mdpi.com
Simple Summary Cisplatin is recognized as the standard agent for head and neck
squamous cell carcinoma therapy, despite the relevant risk of permanent hearing damage …
squamous cell carcinoma therapy, despite the relevant risk of permanent hearing damage …
A Comparison of Fas-Fas Ligand Mediated Apoptosis with Clinical and Pathological Parameters in Larynx Cancers; Twenty Years After Laryngectomy
AM Bilgili, T Ersözlü - The Turkish Journal of Ear Nose and Throat, 2022 - dergipark.org.tr
Objective: Larynx cancer constitutes 2% of all cancers in adults with 96% of larynx
malignancies being squamous cell carcinoma (SHC). Apoptosis is a cell death mechanism …
malignancies being squamous cell carcinoma (SHC). Apoptosis is a cell death mechanism …
[PDF][PDF] MARIA APARECIDA CURSINO
N MATE - repositorio.unicamp.br
Head and neck cancer (HNC) is the set of malignant tumours located in the upper
aerodigestive tract and the therapy is based on radiotherapy concomitant with highdose …
aerodigestive tract and the therapy is based on radiotherapy concomitant with highdose …